Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

Paramore, 2004, Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases, Pharmacoeconomics, 22, 275, 10.2165/00019053-200422050-00001 Nair, 2010, Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis, Lancet, 375, 1545, 10.1016/S0140-6736(10)60206-1 Boyce, 2000, Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid, J Pediatr, 137, 865, 10.1067/mpd.2000.110531 Moler, 1992, Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience, Crit Care Med, 20, 1406, 10.1097/00003246-199210000-00008 Horn, 2003, Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes, J Pediatr, 143, S133, 10.1067/S0022-3476(03)00509-2 Langley, 2011, Epidemiology and prevention of respiratory syncytial virus infections among infants and young children, Pediatr Infect Dis J, 30, 510, 10.1097/INF.0b013e3182184ae7 Welliver, 2010, Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children, Curr Med Res Opin, 26, 2175, 10.1185/03007995.2010.505126 Kneyber, 2000, Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review, Acta Paediatr, 89, 654, 10.1111/j.1651-2227.2000.tb00359.x Banerji, 2009, Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants, Pediatr Infect Dis J, 28, 702, 10.1097/INF.0b013e31819df78e Evers, 1982, Morbidity in Canadian Indian and non-Indian children in the first year of life, Can Med Assoc J, 126, 249 Evers, 1983, Morbidity in Canadian Indian and non-Indian children in the second year, Can J Public Health, 74, 191 Shay, 1999, Bronchiolitis-associated hospitalizations among US children, 1980–1996, JAMA, 282, 1440, 10.1001/jama.282.15.1440 Singleton, 2006, Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season, Pediatr Infect Dis J, 25, 1116, 10.1097/01.inf.0000245104.26996.57 Bockova, 2002, Respiratory syncytial virus infection in Navajo and White Mountain Apache children, Pediatrics, 110, e20, 10.1542/peds.110.2.e20 Stockman, 2012, Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006, Pediatr Infect Dis J, 31, 5, 10.1097/INF.0b013e31822e68e6 Holman, 2004, Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population, Pediatrics, 114, e437, 10.1542/peds.2004-0049 2009, From the American Academy of Pediatrics: policy statements—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections, Pediatrics, 124, 1694, 10.1542/peds.2009-2345 Hu, 2003, Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR, J Clin Microbiol, 41, 149, 10.1128/JCM.41.1.149-154.2003 Carbonell-Estrany, 2010, Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial, Pediatrics, 125, e35, 10.1542/peds.2008-1036 Abarca, 2009, Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children, Pediatr Infect Dis J, 28, 267, 10.1097/INF.0b013e31818ffd03 Simoes, 2007, Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing, J Pediatr, 151, 34, 10.1016/j.jpeds.2007.02.032 1998, Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants, Pediatrics, 102, 531, 10.1542/peds.102.3.531 Feltes, 2003, Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease, J Pediatr, 143, 532, 10.1067/S0022-3476(03)00454-2 Blanken, 2013, Respiratory syncytial virus and recurrent wheeze in healthy preterm infants, N Engl J Med, 368, 1791, 10.1056/NEJMoa1211917 Hall, 2009, The burden of respiratory syncytial virus infection in young children, N Engl J Med, 360, 588, 10.1056/NEJMoa0804877 Regnier, 2013, Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis, Pediatr Infect Dis J, 32, 820, 10.1097/INF.0b013e31829061e8 Simoes, 2010, The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children, J Allergy Clin Immunol, 126, 256, 10.1016/j.jaci.2010.05.026 Karron, 2012, Respiratory syncytial virus and parainfluenza virus vaccines, 1146 Robbie, 2013, A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults, Antimicrob Agents Chemother, 57, 6147, 10.1128/AAC.01285-13